Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment.

We classified 45 AML patients not considered fit for intensive treatment into 3 groups: standard dose VEN (Group A), shorter duration of VEN (Group B), and dose reduction of VEN (Group C). CRc rates were 58, 73, and 72% in Groups A, B, and C, respectively. EFS and OS were significantly shorter in Group A than in Groups B and C. The incidence of FN and severe neutropenia was lower in Groups B (73% and 27%) and C (78% and 44%) than in Group A (92% and 67%). The number of treatment cycles was lower in Group A (7.5) than in Groups B (10.2) and C (15.5). The present study showed that shortening the duration and reducing the dose of VEN may reduce the risk of complications and be as effective as standard dose VEN for the treatment of AML patients not considered fit for intensive treatment.